Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)1 and OXB,1 today announce the start of LENTICLAIRTM 1, a Phase I/II trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback